Empowering clinicians with technologies that solve real challenges.
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. Since 2016, the company has created products that empower healthcare providers by optimizing efficiency, improving accuracy, and increasing precision.
Keya Medical’s team of over 400 employees combines expertise in deep learning, computer vision, medical image processing, fluid dynamics, and medical robotics. Many of our research and development team members previously worked at world renowned medical device companies and were deeply involved in the successful development of leading medical devices. Our multidisciplinary expertise allows us to provide solutions that address the most pressing challenges facing clinicians today.
Keya Medical has developed solutions for specialties including cardiology, neurology, radiology, pathology, and surgery. We are proud to collaborate with over 725 hospitals worldwide to bring solutions to clinical use that improve diagnostics, care processes, and clinical outcomes.
To create the next generation of advanced diagnostics and precision therapeutics that solve real clinical challenges.
Realizing the full potential of AI to improve care delivery on a global scale.
AI augments clinical effectiveness
Empower clinicians to optimize efficiency & improve care delivery
Ensure solutions increase accuracy and reproducibility
Deliver clinical value throughout the patient care process
By the Numbers
- December 2020
Keya Medical raises $46 million in Series D funding
- November 2020
Keya Medical closes $30 million in Series C funding
- September 2020
Keya Medical is awarded China’s Most Promising Company Award by Ernst & Young Fudan China
CuraRad-ICH joins Nuance AI Marketplace for Diagnostic Imaging
- August 2020
Keya Medical closes $20 million in Series B+ funding
- March 2020
CuraRad-ICH receives U.S. FDA 510(k) clearance
- February 2020
Keya Medical raises over $15 million in strategic funding
- January 2020
DeepVessel FFR becomes the first Class-III AI medical device approved for clinical use by the Chinese National Medical Products Administration
- December 2019
Keya Medical is selected to the Top 100 Medical Companies of the Future list by VCBeat Research
- August 2018
DeepVessel FFR receives CE certification
- June 2018
Keya Medical receives ISO 13485 certification
- April 2018
DeepVessel FFR enters the CFDA Special Approval Channel for Innovative Medical Devices
- October 2017
Keya Medical establishes the first AI diagnostic laboratory in China
- January 2016
Keya Medical is founded
We offer potential investors an opportunity to drive the commercial development of medical AI products.
Keya Medical has raised $46 million in Series D funding. This funding round was led by new and existing investors, including CICC Capital, Shanghai Artificial Intelligence Investment Fund, Qianhai Gaozu Asset Management Fund, and IN CAPITAL.
Keya Medical announced that it has completed a $30 Million Series C Funding Round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
Keya Medical announced on Aug. 13 that it has raised over $20 million in Series B+ funding.